Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production

Journal of Medical Virology

Volumn 50, Issue 4, 1996, Pages 283-288

  Zuckerman, Jane N ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B; Nonresponse; Vaccines

Indexed keywords

HEPATITIS B VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; HAPLOTYPE; HEPATITIS B; HLA SYSTEM; HUMAN; KINETICS; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; DISEASE SUSCEPTIBILITY; GENES, MHC CLASS I; GENES, MHC CLASS II; HAPLOTYPES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KINETICS; VACCINATION;

HEPATITIS B VIRUS;

EID: 0029846451     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4     Document Type: Review

References (62)

1. Alberti A, Cavalletto D, Pontisso P, Chemello L, Tagariello G, Belussi F (1988): Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet I:1421-1424.
2. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ (1989): Genetic prediction of nonresponse to hepatitis B vaccine. The New England Journal of Medicine 321:708-712.
3. Ambrosch F, Frisch-Niggemeyer W, Kremsner P, Kunz Ch, Andre F, Safary A, Wiedermann G (1987): Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgraduate Medical Journal 63(Suppl 2):129-135.
4. Arif M, Mitchison NA, Zuckerman AJ (1988): Genetics of nonresponders to hepatitis B surface antigen and possible ways of circumventing "nonresponse." In Zuckerman AJ (ed.): "Viral Hepatitis and Liver Disease." New York: Alan R. Lisa, pp 714-716.
5. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H, Bonino F (1991): Wildtype and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proceedings of the National Academy of Sciences, USA 88:4186-4190.
6. Centers for Disease Control (1991): Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Morbidity & Mortality Weekly Report 40(RR-13):1-19.
7. Clements ML, Miskovsky E, Davidson M, Cupps T, Kumwenda N, Sandman LA, West D, Hesley T, Loli V, Miller W, Calandra G, Krugman S (1994): Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or pre-S2 + S antigens. Journal of Infectious Diseases 170:510-516.
8. Courouće A-M, Laplanche A, Benhamou E, Jungers P (1988): Long-term efficacy of hepatitis B vaccine in healthy adults. In Zuckerman AJ (ed.): "Viral Hepatitis and Liver Disease." New York: Alan R. Liss, pp 1002-1005.
9. Coursaget P, Yvonnet B, Chotard J-N, Sarr M, Vincelot P, N'Doye R, Diop-Mar I, Chiron JP (1986): Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 2:1143-1145.
10. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Diesstag JL, Werner BG, Polk F, Snydman DR, Platt R, Crumpacker CS, Grady GF, Alper CA (1986): Nonresponsiveness to hepatitis B vaccine in health care workers. Annals of Internal Medicine 105:356-360.
11. Dienstag JL, Werner BG, Polk F, Snydman DR, Craven DE, Platt R, Crumpacker CS. Ouellet-Hellstrom R, Grady GF (1984): Hepatitis B vaccine in health care personnel: Safety, immunogenicity, and indicators of efficacy. Annals of Internal Medicine 101:34-40.
12. Fagan EA, Trolley P, Smith H, Peters MP, Coleman J, Elliott P, Williams R, Eddleston ALWF (1987a): Hepatitis B vaccine: Immunogenicity and follow-up including two year boosters doses in high risk health personnel in a London teaching hospital. Journal of Medical Virology 21:49-56.
13. Fagan E, Williams R, Eddleston ALWF (1987b): Hepatitis B vaccine: Responder status and timing of additional booster doses. Lancet 2:561.
14. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G, Pilli M, Vitali P, Neri TM, Giuberti T, Fiaccadori F (1992): Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 103:255-263.
15. Flower AJE, Tanner MS (1988): Use of hepatitis B vaccine in babies of hepatitis B surface antigen-positive carrier mothers. In Zuckerman AJ (ed): "Viral Hepatitis and Liver Disease." New York; Alan R. Liss, pp 980-981.
16. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, Braff EH, O'Malley P, Hawkins D, Judson FN, Penley K, Nylund T, Christie G, Meyers F, Moore JN, Gardner A, Doto IL, Miller JH, Reynolds GH, Murphy BL, Shable CA, Clark BT, Curren JW, Redeker AG (1982): The prevention of hepatitis B with vaccine. Annals of Internal Medicine 97:362-366.
17. Gerlich WH, Deepen R, Heermann KH, Krone B, Lu XY, Seifer M, Thomssen R (1990): Protective potential of hepatitis B virus antigens other than the S gene protein. Vaccine 8:S63-S68.
18. Gibas A, Watkins E, Hinkle C Dienstag J (1988): Long term persistence of protective antibody after hepatitis B vaccination of healthy adults. In Zuckerman AJ (ed): "Viral Hepatitis and Liver Disease." New York: Alan R. Liss, pp 998-1001.
19. Goldwater PN (1994): Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 12:410-414.
20. Grob PJ, Joller-Jemelka HI, Binswanger U, Zaruba K, Descoeudres C, Fernex M (1984): Interferon as an adjuvant for hepatitis B vaccination in non and low-responder populations. European Journal of Clinical Microbiology 3:195-198.
21. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA, Altman NL, Braff E, Shipman GF, Coleman PJ, Mandel EJ (1986): Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New England Journal of Medicine 315:209-214.
22. Hadler SC, Coleman PJ, O'Malley P, Judson FN, Altaian N (1991): Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In Hollinger FB, Lemon SB, Margolis HS (eds). "Viral Hepatitis and Liver Disease." Baltimore: Williams & Wilkins, pp 766-768.
23. Hall AJ (1993): Hepatitis B vaccination: Protection for how long and against what? British Medical Journal, 307:276-277.
24. Hilleman MR (1984): Immunologic prevention of human hepatitis. Perspective in Biology and Medicine, 27:543-557.
25. Jilg W, Schmidt M, Deinhardt F, Zachoval R (1984): Hepatitis B vaccination: How long does protection last? Lancet 2:458.
26. Jilg W, Schmidt M, Deinhardt F (1988): Immune response to hepatitis B revaccination. Journal of Medical Virology 24:377-384.
27. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM (1994): Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 344:856-857.
28. Klinkert M, Theilmann L, Pfaff E, Schaller H (1986): Pre-S antigens and antibodies early in the course of acute hepatitis B virus infection. Journal of Virology 52:522-525.
29. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D (1992): The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. Journal of Experimental Medicine 175: 495-502.
30. Lou K-X, Wang L-P, Nie J, Jiang S (1992): Is non-responsiveness to hepatitis B vaccine due to latent hepatitis B virus infection? Journal of Infectious Diseases 165:777-778.
31. Marescot MR, Budkowska A, Pillot J, Debre P (1989): HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination. Tissue Antigens 33:495-500.
32. Maupas Ph, Goudeau A, Coursaget P, Drucker J, Barin F, Andre M (1979): Immunization against hepatitis B in man: A pilot study of two years' duration. In Vyas GN, Cohen SN, Schmid R (eds): "Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention." Philadelphia: Franklin Institute Press, pp 359-556.
33. McDermott AB, Zuckerman JN, Sabin CA, Madrigal JA (1996): HLA haplotypes in non-responders to hepatitis B vaccine and in response to a novel recombinant vaccine. (Submitted).
34. McIntyre PJ (1995): Hepatitis B vaccination follow-up. Lancet 345:1575.
35. Melappioni M, Baldassari M, Saldini S, Radicioni R, Panichi N (1992): Use if immunomodulators (Thymopentin) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis. Nephron 61:358-359.
36. Meuer SC, Dumann H, Meyer zum Buschenfelde K-H, Kohler H (1989): Low dose interleukin-2 induces systemic immune responses against Hbs Ag in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-17.
37. Milich DR (1991): Immune response to hepatitis B virus proteins: Relevance of the murine model. Seminars in Liver Disease 11:93-112.
38. Milich DR, McNamara NK, McLachlan A, Thornton GB, Chisari FV (1985a): Distinct H-2 linked regulation of T-cell responses to the Pre-S and S regions of the same hepatitis B surface polypeptide allows circumvention of nonresponsiveness to the S region. Proceedings of the National Academy of Sciences USA 82:8168-8172.
39. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel M-L, Tiollais P, Chisari FV (1985b): Enhanced immunogenicity of the Pre-S region of hepatitis B surface antigen. Science 228:1195-1199.
40. Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB (1986): Immune response to the pre-S(1) region of hepatitis B surface antigen (HBsAg): A pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg. Journal of Immunology 137:315-322.
41. Nommensen FE, Go ST, MacLaren DM (1989): Half-life of HBs antibody after hepatitis B vaccination: An aid to timing of booster vaccination. Lancet 2:847-849.
42. Oldstone MBA (1989): Viral persistence. Cell 56:517-552.
43. Paller AS, Mallory SB (1991): Acquired forms of immunosuppression. Journal of the American Academy of Dermatology 24:482-488.
44. Pasko MT, Pharm D, Beam TR Jr (1990): Persistence of anti-Hbs among health care personnel immunized with hepatitis B vaccine. American Journal of Public Health 80:590-593.
45. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH (1994): Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453-1459.
46. Stevens CE, Alter HJ, Taylor PE, Zaug EA, Harley EJ, Szmuness W (1984a): Hepatitis B vaccine in patients receiving haemodialysis: Immunogenicity and efficacy. New England Journal of Medicine 311:496-501.
47. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN (1984b): Hepatitis B vaccine: An overview. In Vyas GN, Dienstag JL, Hoofnagle JH (eds): "Viral Hepatitis and Liver Disease." Orlando: Grune and Stratton, pp 275-291.
48. Suzuki H, Lino S, Shiraki K, Akahane Y, Okamoto H, Domoto K, Mishiro S (1994): Safety and efficacy of a recombinant yeast-derived pre-S2 +-S-containing hepatitis B vaccine (TGP-943): Phase I, 2, and 3 clinical testing. Vaccine 12:1090-1095.
49. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A (1981): A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B). A Final Report. Hepatology 1:377-385.
50. Taylor PE, Stevens CE (1988): Persistence of antibody to hepatitis B surface antigen after vaccination with hepatitis B vaccine. In Zuckerman AJ (ed): "Viral Hepatitis and Liver Disease." New York: Alan R. Liss, pp 995-997.
51. Tedder RS, Zuckerman MA, Brink N (1993): Hepatitis B vaccination: Non-responders must be detected. Lancet 307:732.
52. Tilzey AJ (1995): Hepatitis B vaccine boosting; the debate continues. Lancet 345:1000-1001.
53. van Hattum J, Maikoe T, Poel J, de Gast GC (1991): In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody. In Hollinger BF, Lemon SM, Margolis H (eds): "Viral Hepatitis and Liver Disease." Baltimore: Williams and Wilkins, pp 774-776.
54. Walker M, Szmuness W, Stevens CE, Rubenstein P (1981): Genetics of anti-HBs responsiveness: HLA DR7 and nonresponsiveness to hepatitis B vaccination. Transfusion 21:601.
55. Westmoreland D, Player V, Heap DC, Hammond A (1990): Immunization against hepatitis B-what can we expect? Epidemiological Infection 104:499-509.
56. Wiseman P, van Hattum J, Mudde GC, Endeman HJ, Poel J, de Gast GC (1989): Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. Journal of Hepatology 8:236-240.
57. Wiseman P, van Hattum J, Stelling T, Poel J, De Gast GC (1988): Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology 35:78-79.
58. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT (1993): Risk factors for lack of detectable antibody response following hepatitis B vaccination of Minnesota health care workers. Journal of the American Medical Association 270: 2935-2939.
59. Yap I, Guan R, Chan SH (1995): Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. Journal of Gastroenterology and Hepatology 10:51-55.
60. Yap I, Guan R, Chan SH (1992): Recombinant DNA hepatitis B vaccine containing pre S-components of the HBV coat protein - a preliminary study of immunogenicity. Vaccine 10:439-442.
61. Zaruba K, Rastorfer M, Grob PJ, Joller-Jemelka H, Bolla K (1983): Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination. Lancet 2:1245.
62. Zuckerman JN, Craig FN, Williams A, Zuckerman AJ (1996): Immunogenicity of a novel triple-S hepatitis B vaccine in nonresponder health care workers. Submitted for publication.